Celgene

Bristol Myers to CEO Caforio: Good job on Celgene so far, but you'll have to work for your raise
Bristol Myers to CEO Caforio: Good job on Celgene so far, but you'll have to work for your raise
Fierce Pharma
Bristol-Myers Squibb
Celgene
executive pay
Giovanni Caforio
Flag link:
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
Flag link:
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Flag link:
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Endpoints
Bristol-Myers Squibb
Celgene
M&A
clinical trials
Multiple Myeloma
Empliciti
AbbVie
Revlimid
Flag link:
Bristol Myers Squibb unveils new branding, will phase out Celgene brand
Bristol Myers Squibb unveils new branding, will phase out Celgene brand
Medical Marketing and Media
Bristol-Myers Squibb
Celgene
rebranding
M&A
Flag link:
A Big Month Ahead for the FDA and Bristol-Myers Squibb
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Motley Fool
Bristol-Myers Squibb
Celgene
FDA
ozanimod
Opdivo
Reblozyl
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
How Bristol-Myers Squibb Trounced Wall Street's Q4 Estimates
How Bristol-Myers Squibb Trounced Wall Street's Q4 Estimates
Motley Fool
Bristol-Myers Squibb
earnings
Celgene
M&A
Flag link:
Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches
Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches
Fierce Pharma
Celgene
Bristol-Myers Squibb
blood cancer
Flag link:
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020
Fierce Pharma
M&A
JPMHC 2020
Bristol-Myers Squibb
Celgene
Giovanni Caforio
Flag link:
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
Flag link:
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Fierce Pharma
Bristol-Myers Squibb
Celgene
CAR-T
M&A
Flag link:
Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto
Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto
Xconomy
Amira Pharmaceuticals
Bristol-Myers Squibb
Celgene
PharmAkea
Galecto Biotech
fibrotic disease
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition
How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Flag link:
After big M&A year, will pharma move away from massive deals in 2020?
After big M&A year, will pharma move away from massive deals in 2020?
Fierce Pharma
M&A
Sanofi
Merck
AbbVie
Allergan
Bristol-Myers Squibb
Celgene
FTC
Flag link:
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Revlimid
patents
Flag link:
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
Motley Fool
Celgene
M&A
Bristol-Myers Squibb
Flag link:
Deal of the Year: Bristol-Myers Squibb buys Celgene
Deal of the Year: Bristol-Myers Squibb buys Celgene
Biopharma Dive
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Motley Fool
Celgene
Editas Medicine
Juno Therapeutics
CRISPR
gene editing
Flag link:

Pages